Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany

Braun S, Mittendorf T, Menschik T, Greiner W, von der Schulenburg J-M (2009)
BREAST CARE 4(6): 389-396.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor
; ; ; ;
Abstract / Bemerkung
Background: Medical studies have shown that switching to exemestane after 2-3 years of adjuvant treatment with tamoxifen is effective when looking at overall survival. No cost effectiveness study of exemestane has been conducted in the German health care context. Patients and Methods: To assess the cost effectiveness of switching to exemestane vs. continued tamoxifen therapy for early-stage breast cancer, a Markov model was developed. The model population was set as postmenopausal women who are in remission from early-stage breast cancer. Upon model entry, either a continuing daily therapy with 20 mg tamoxifen or a switch to 25 mg exemestane for the next 2-3 years takes place. The model takes a German health care perspective. Results: The total incremental costs of exemestane on a lifetime basis are 4,195 Euro, resulting in an incremental cost effectiveness ratio of 17,632 Euro per additional quality-adjusted life year (QALY), or 16,857 Euro per life year gained. Incremental costs per disease-free year of survival are 12,851 Euro. Probabilistic sensitivity analyses proved the robustness of these findings. Conclusion: Compared to extended tamoxifen therapy, switching to exemestane after 2-3 years turned out to be a cost-effective strategy in adjuvant therapy for early-stage breast cancer in postmenopausal women within the German health care context.
Erscheinungsjahr
Zeitschriftentitel
BREAST CARE
Band
4
Ausgabe
6
Seite(n)
389-396
ISSN
eISSN
PUB-ID

Zitieren

Braun S, Mittendorf T, Menschik T, Greiner W, von der Schulenburg J-M. Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany. BREAST CARE. 2009;4(6):389-396.
Braun, S., Mittendorf, T., Menschik, T., Greiner, W., & von der Schulenburg, J. - M. (2009). Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany. BREAST CARE, 4(6), 389-396. doi:10.1159/000255840
Braun, S., Mittendorf, T., Menschik, T., Greiner, W., and von der Schulenburg, J. - M. (2009). Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany. BREAST CARE 4, 389-396.
Braun, S., et al., 2009. Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany. BREAST CARE, 4(6), p 389-396.
S. Braun, et al., “Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany”, BREAST CARE, vol. 4, 2009, pp. 389-396.
Braun, S., Mittendorf, T., Menschik, T., Greiner, W., von der Schulenburg, J.-M.: Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany. BREAST CARE. 4, 389-396 (2009).
Braun, Sebastian, Mittendorf, Thomas, Menschik, Thomas, Greiner, Wolfgang, and von der Schulenburg, Johann-Matthias. “Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany”. BREAST CARE 4.6 (2009): 389-396.

6 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

A method for using real world data in breast cancer modeling.
Pobiruchin M, Bochum S, Martens UM, Kieser M, Schramm W., J Biomed Inform 60(), 2016
PMID: 26854868
Cost-utility analyses of drug therapies in breast cancer: a systematic review.
Nerich V, Saing S, Gamper EM, Kemmler G, Daval F, Pivot X, Holzner B., Breast Cancer Res Treat 159(3), 2016
PMID: 27572551
Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomes.
Frederix GW, Severens JL, Hövels AM, Raaijmakers JA, Schellens JH., Value Health 15(1), 2012
PMID: 22264977
Exemestane in the adjuvant treatment of breast cancer in postmenopausal women.
Kittaneh M, Glück S., Breast Cancer (Auckl) 5(), 2011
PMID: 22084574

28 References

Daten bereitgestellt von Europe PubMed Central.

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial.
Boccardo F, Rubagotti A, Guglielmini P, Fini A, Paladini G, Mesiti M, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P., Ann. Oncol. 17 Suppl 7(), 2006
PMID: 16760270
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup Exemestane Study., Lancet 369(9561), 2007
PMID: 17307102
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL., J. Natl. Cancer Inst. 97(17), 2005
PMID: 16145047
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J; ABCSG and the GABG., Lancet 366(9484), 2005
PMID: 16084253
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
Breast International Group (BIG) 1-98 Collaborative Group, Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Wardly A, Price KN, Goldhirsch A., N. Engl. J. Med. 353(26), 2005
PMID: 16382061
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR., J. Clin. Oncol. 23(3), 2004
PMID: 15545664

AUTHOR UNKNOWN, 0
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C; Intergroup Exemestane Study., N. Engl. J. Med. 350(11), 2004
PMID: 15014181

AUTHOR UNKNOWN, 0
German recommendations on health economic evaluation: third and updated version of the Hanover Consensus.
Graf von der Schulenburg JM, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, Mittendorf T, Rebscher H, Schoeffski O, Vauth C, Volmer T, Wahler S, Wasem J, Weber C; Hanover Consensus Group, Adam H, Jurgen Ahrens H, Boehnke A, Breyer F, Cassel D, Doerner R, Felder S, Flessa S, Frick M, Goertz A, Hansen L, Happich M, Haeussler B, Hebel D, Henke KD, Hessel F, Hilf C, Jaecker A, Jacobs K, Kailuweit I, Kifmann M, Knappe E, Kohlmann T, Koenig HH, Kraemer W, Leu RE, Marhoefer M, Meidenbauer T, Merkesdal S, Mueller R, Mueller U, Munte A, Neubauer G, Oberender P, Osowski U, Peter J, Raffelhueschen B, Rauner K, Resch A, Ried W, Ruether A, Runge C, Rychlik R, Schmeinck W, Schnorpfeil W, Schulte G, Schultes HJ, Schulze-Solce HN, Scriba P, Selbmann HK, Siebert U, Spiro TC, Ulrich V, Voecking J, Werner I, Wille E, Willich SN, Yzer C., Value Health 11(4), 2008
PMID: 18194408
Treatment of early-stage breast cancer in the elderly: a health-outcome-based approach.
Carter KJ, Ritchey NP, Castro F, Caccamo LP, Kessler E, Erickson BA, Gawdyda LM., Med Decis Making 18(2), 1998
PMID: 9566454

AUTHOR UNKNOWN, 0
Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study.
Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D, Jonsson B., Osteoporos Int 16(1), 2004
PMID: 15672210
Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis.
Ozanne EM, Esserman LJ., Cancer Epidemiol. Biomarkers Prev. 13(12), 2004
PMID: 15598759
Tamoxifen for breast cancer prevention: a framework for clinical decisions.
Cykert S, Phifer N, Hansen C., Obstet Gynecol 104(3), 2004
PMID: 15339751
Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.
Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM., Cancer 97(3), 2003
PMID: 12548595
Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer.
Abner AL, Recht A, Eberlein T, Come S, Shulman L, Hayes D, Connolly JL, Schnitt SJ, Silver B, Harris JR., J. Clin. Oncol. 11(1), 1993
PMID: 8418240

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0
Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer.
Thompson D, Taylor DC, Montoya EL, Winer EP, Jones SE, Weinstein MC., Value Health 10(5), 2007
PMID: 17888101

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 20877674
PubMed | Europe PMC

Suchen in

Google Scholar